Kintara shareholders approve issuance of >20% of common stock to Lincoln Park Capital Fund

TuHURA Biosciences, Inc./NV

At special meeting Oct 9, 2023, Proposal 1 (issuance >20% of common stock to Lincoln Park Capital Fund) approved with 644,145 FOR, 39,208 AGAINST.
Proposal 2 (adjournment if needed) also approved: 647,100 FOR, 36,634 AGAINST, 1,841 ABSTAIN.
Approval permits Kintara to issue additional shares under the purchase agreement for capital raising.
Dilution of existing shareholders likely given the issuance of more than 20% of outstanding common stock.

Key facts

Extracted from this filing and checked against the source text.

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

TuHURA Biosciences, Inc./NV shareholders approved Approve adjournment of special meeting if needed at the 2023-10-09 meeting.

Outcome: passed
Meeting: 2023-10-09

Exact text from the filing

The votes cast with respect to the proposal to approve the adjournment of the Special Meeting in the event that the number of shares of the Company’s common stock and Series C Preferred Stock present or represented by proxy at the Special Meeting and voting “FOR” the adoption of Proposal 1 were insufficient were as follows: FOR AGAINST ABSTAIN BROKER NON-VOTES 647,100 36,634 1,841 0

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

TuHURA Biosciences, Inc./NV shareholders approved Approve issuance of more than 20% of common stock under purchase agreement with Lincoln Park Capital Fund, LLC at the 2023-10-09 meeting.

Outcome: passed
Meeting: 2023-10-09

Exact text from the filing

The votes cast with respect to the proposal to approve, for purposes of complying with Nasdaq Listing Rule 5635(d), the issuance of more than 20% of the Company’s issued and outstanding common stock pursuant to the Company’s purchase agreement with Lincoln Park Capital Fund, LLC were as follows: FOR AGAINST ABSTAIN BROKER NON-VOTES 644,145 39,208 2,222 0

View on SEC.gov

147 shareholder votes filed in the last 30 days. Browse all shareholder votes →

TuHURA Biosciences, Inc./NV filing history →

Source: SEC EDGAR

accession 0000950170-23-052626

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.